Navigation Links
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
Date:9/3/2009

nes against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). Factors affecting the development and use of DOR201 and LPM(TM) are similar to those affecting orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 1
'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
2. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
5. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
6. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
7. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
8. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
9. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Best Sanitizers, Inc., the first company ... sanitizer, asks food processors and food handling professionals to ... they’re currently using to Best Sanitizers’ Alpet® E3 ... to fighting cross-contamination and the spread of pathogens in ... are key criteria that make a hand sanitizer most ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Say Biovail seeing tide changing against management - with ... at meeting, secretly met to change rules, TORONTO, ... said that their lawyers will be in court today ... BVF ) Annual General Meeting,was illegally held and ...
... Md., June 25 Martek Biosciences,(Nasdaq: MATK ... of DHA-omega 3 essential for infant brain and ... in the new Pregnium prenatal,supplement from Walmark. Featuring ... at major retailers in the Czech Republic, Slovakia,and ...
... Pharmaceuticals to develop drug candidate for prevention and ... function in kidney transplantation, LONDON, June 25 ... that the U.S. Food and Drug Administration (FDA) ... Drug,application (IND) for an siRNA therapeutic product based ...
Cached Biology Technology:Eastern European Supplement Leader Walmark Launches Prenatal Product Featuring Martek's life'sDHA(TM) 2Eastern European Supplement Leader Walmark Launches Prenatal Product Featuring Martek's life'sDHA(TM) 3FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry 2FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry 3
(Date:8/28/2014)... for measuring and imaging how quickly blood flows in ... how drug abuse affects the brain, which may aid ... to better treatment options for recovering drug addicts. The ... Stony Brook University in New York, USA and the ... The Optical Society,s (OSA) open-access journal Biomedical ...
(Date:8/28/2014)... release is available in German . ... are now built with the help of sophisticated assembly lines. ... are an important part of these assembly lines. In the ... in various work stages arranged in a precise spatial and ... of the line. , The creation of such an assembly ...
(Date:8/28/2014)... northern California, and Alaska totaled 515 million board feet ... increase of more than 10 percent compared to the ... Northwest Research Station reported today. During this same period, ... 247 million board feet. , The total value of ... to $390 million in the same quarter, while the ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Nanoscale assembly line 2Nanoscale assembly line 3West coast log exports up, lumber exports down in second quarter of 2014 2
... when they invade other tissues in the body could ... them, a research group led by led by Bradley ... and cellular biology reports in Nature Cell Biology ... Ciona intestinalis , the researchers discovered that even non-invasive ...
... 2011 Case Western Reserve University School of Medicine has received ... Resources, part of the National Institutes of Health (NIH), to ... (CF). CF is an inherited disease that causes thick, ... tract. The four-year NIH grant was awarded to Mitchell Drumm, ...
... in Seattle have worked to solve the mystery of why ... they return from the ocean to mate and spawn. In ... the team use models to estimate the potential impact ... decades ahead. Stricken coho salmon ( Oncorhynchus kisutch ) ...
Cached Biology News:Sea squirt cells shed light on cancer development 2Sea squirt cells shed light on cancer development 3Sea squirt cells shed light on cancer development 4CWRU receives $2.1 million NIH grant to expand cystic fibrosis research models 2Models show Coho salmon at risk in US urbanizing watersheds 2
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rab1A...
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Biology Products: